Kanker-actueel Chemo hyperthermia (Hypec operation) in metastatic peritoneal cancer (colonrectalcancer) of adenocarcinoomtype provides significantly longer survival results, but many serious side effects and 80% will relapse despite a stud says

CANCER.

Information on current developments in both regular and alternative or complementary treatments for cancer types and resources at all stages. We have basically all articles and information put in alphabetical order, scroll in left column in alphabetical list.

Experiences of cancer patients with complementary approaches can be found by experience stories and there are also some videos of experiences of cancer patients to see. To click on video button top left . Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

Chemo hyperthermia (Hypec operation) in metastatic peritoneal cancer (colonrectalcancer) of adenocarcinoomtype provides significantly longer survival results, but many serious side effects and get 80% despite a relapse in the study said Antonie van Leeuwenhoek Hospital.

dated April 12, 2004: Hypec operation appears to be effective for cancer patients with metastases to the peritoneum. A comparative method of treatment as the article about IPHC , removal of metastases in the peritoneum from colon cancer while heating ( hyperthermia ) of the peritoneum and tissue surrounding the resected tumor tissue for this study is done in the Antonie van Leeuwenhoek Hospital and published in October 2003 in the Journal of Clinicial Oncology. Here a media message from this study and the abstract below, which strikes people with 5 or more metastases is still a very poor prognosis. And unfortunately those with metastases adenocarcinamo from the gut to the peritoneum often quick 5 or more metastases. Moreover, the same research team published alongside the jubilant figures also an outcome study on the effects of a HYPEC treatment. These are not mentioned extensively in the media, even silence, but who reads the abstract scares them. As many as 65% (NCI CTC Grade 3-5) of participating patients experienced serious side effects, including bowel perforation and even eight patients (approx. 13%) died during or following the Hypec treatment. The opinion of the research team is that which more than 5 metastases, would be better off without a HYPEC treatment. Mr. B. was not eligible for a HYPEC or any regular treatment and therefore did / does it his way. He has lived two years without major symptoms or tumor growth, especially by consistently following the Houtsmuller Diet, and extra food to supplement methylglyoxal. LONDON (Reuters) - Patients with colorectal cancer metastases solely on their peritoneum, have a chance of living longer thanks to a new treatment method. This according to a study by Dr. F. Zoetmulder and Dr. V. Verwaal of the Dutch Cancer Institute / Antoni van Leeuwenhoek hospital in Amsterdam. Their findings are Wednesday in the American Journal of Clinical Oncology. Zoetmulder Verwaal and compared the treatment of this group of patients who receive chemotherapy alone through the bloodstream to the so-HIPEC treatment. This is after the surgical removal of metastases in the peritoneum of the abdominal cavity flushed with heated chemotherapy. The investigation showed that the average survival of patients who underwent HIPEC method, doubled. Moreover, it led to one in five patients, but also a prolonged survival, which in the medical world faces a period of five years or more. This comes after the usual chemotherapy in this disease is very rare. An estimated 200 patients every year in the Netherlands who may benefit from this treatment. Especially patients whose disease has not overgrown the entire abdomen and in whom manage to remove all visible cancer tissues, benefit from the HIPEC treatment. Per year in approximately 8800 with cancer of the colon or rectum diagnosed. Every year over 4400 people die from this disease. It happens to most by metastasis in the liver. Metastases in the peritoneum is number two cause of death. Source: J Clin Oncol. 2003 Oct 15, 21 (20) :3737-43. Randomized trial of cytoreduction and intraperitoneal hyperthermia chemotherapy versus systemic chemotherapy and Palliative Surgery in Patients with Peritoneal carcinomatosis of colorectal cancer. Verwaal VJ, van Ruth S, de Bree E, Sloothen GW, Tint Eren H, Boot H, Zoetmulder FA. Department of Surgery, Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. v.verwaal @ nki.nl PURPOSE: To confirm the Findings from uncontrolled studies That aggressive cytoreduction in combination with hyperthermia intraperitoneal chemotherapy (HIPEC) is superior to standard treatment in patient with Peritoneal carcinomatosis of colorectal cancer origin. PATIENT AND METHODS: Between February 1998 and August 2001, 105 Patients Were Randomly Assigned to Receive Either standard treatment more consistent or systemic chemotherapy (fluorouracil-leucovorin) with or Without Palliative surgery, or experimental therapy more consistent and aggressive cytoreduction with HIPEC, followed by The Same systemic chemotherapy regimen. The primary end point was survival. RESULTS: After a median follow-up period of 21.6 months, the median survival was 12.6 months in the standard therapy arm and 22.3 months in the experimental therapy arm (log-rank test, P =. 032). The treatment-related mortality in the aggressive therapy group was 8%. Most Complications from HIPEC Were related to bowel leakage. Subgroup analysis of theThat HIPEC group showed patiënten with 0 to 5 of the 7 regions of the abdominal cavity Involved by tumor at the time of the cytoreduction had a significantly better survival Than patiënten with 6 or 7, affected regions (log-rank test, P <.0001) . If the cytoreduction was macroscopically complete (R-1), the median survival was significantly better than in patiënten Also with limited (R-2a), or extensification residual disease (R-2b, log-rank test, P <.0001). CONCLUSION: Cytoreduction followed by HIPEC improves survival in Patients with Peritoneal carcinomatosis of colorectal origin. However, patient involvement, or with six or more regions of the abdominal cavity, or grossly incomplete cytoreduction, had still a grave prognosis. Here is the abstract about the side effects of treatment as an addition to the above-HYPEC published in the Journal of Clinical Oncology. Toxicity of cytoreductive surgery and intraperitoneal hyperthermia chemotherapy. Verwaal VJ, Tint Eren H, Ruth SV, Zoetmulder FA. Department of Surgery, The Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. v.verwaal @ nki.nl BACKGROUND AND OBJECTIVES: Cytoreduction hyperthermia with intra-peritoneal chemotherapy (HIPEC) is a treatment with a high morbidity. Optimal patient selection can-Possible Complications and reducing toxicity. PATIENT AND METHODS: Complications and toxicity or Were studied 102 patients. Toxicity was graded accordion thing National Cancer Institute Common Toxicity Criteria (NCI CTC) classification. A complication was defined as post-operative Any Events that Needed re-intervention. Potential patient, tumor and treatment factors studied Were On Their Relation to Complications. RESULTS: Grade 3, 4, or 5 toxicity was observed in 66 patients (65%). Eight died patiënten or treatment-related Causes. Surgical Complications occurred in 36 patients (35%). Were Encountered frequently fistulae (18 patients). The risk of a Complicated recovery was higher in recurrent colorectal cancer with carcinomatosis (P = 0.009) and in the case of More Than Five Affected regions (P = 0.044), who had a Simplified Peritoneal Cancer (SPC) score or 13 (P = 0012) and with an incomplete initial cytoreduction (P = 0.035). Patients with blood loss Exceeding 6 L (P = 0.028) and Those with three or more anastomoses Also had an Increased post-operative complication rate (P = 0.018). CONCLUSIONS: Toxicity of cytoreduction followed by HIPEC was 65% (NCI CTC Grade 3-5), with a Surgical complication rate of 35%. Patients with six or seven regions and Those Involved in Whom are complete cytoreduction can not be Reached Probably better off without this treatment. Copyright 2004 Wiley-Liss, Inc.. Here is the abstract of the annex on risk of recurrence (return of cancer) after a HYPEC treatment. look into this and was given nothing to read in the media, but 80% relapse after a very serious surgery and treatment is not exactly rejoicing over news seems to us. Recurrences after Peritoneal carcinomatosis of colorectal origin Treated by hyperthermia cytoreduction and intraperitoneal chemotherapy: location, treatment, and outcome. Verwaal VJ, Boot H, Aleman BM, Van Hue Eren H, Zoetmulder FA. The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. v.verwaal @ nki.nl. BACKGROUND: After treatment or peritoneal carcinomatosis of colorectal cancer origin by cytoreduction and intraperitoneal hyperthermia chemotherapy (HIPEC), initially develop recurrences in approximately 80% or patients. This study evaluates the outcome or Such recurrences after initial treatment by cytoreduction and HIPEC. METHODS: Between November 1995 and May 2003, 106 patients under went cytoreduction and HIPEC. The progression-free interval, the location of the Recurrence, and Its Treatment Were recorded. Potentially factors related to survival after recurrences Were studied. RESULTS: Sixty-nine patient experienced a Recurrence Within the study period. Patients who had gone for a gross understatement incomplete initial cytoreduction, the median duration of survival after Recurrence was 3.7 months (standard error of the mean [SE], .3). If a complete cytoreduction had leg accomplished initially, the median duration of survival after the Recurrence was 11.1 months (SE, .9). A Shorter Interval between HIPEC and Recurrence was associated with Shorter Survival or Recurrence after treatment (hazard ratio, .94, SE .02). After effective initial treatment, a second Surgical debulking for recurrent disease resulted in a median survival duration of 10.3 months (SE, 1.9), and after treatment with chemotherapy it was 8.5 months (SE, 1.6). The survival was 11.2 months (SE, .5) for Patient who Received radiotherapy for recurrent disease. Patients who did not receive Further treatment survived 1.9 months (SE, .3). CONCLUSIONS: Treatment of Recurrence after cytoreduction and HIPEC isOften Seems Feasible and Worthwhile in selected patient. Selection Should Be Mainly based on the completeness of the Interval between initial cytoreduction and HIPEC and Recurrence. PMID: 15070596 [PubMed - in process]